Expression of Ezrin,HGF,C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats

被引:7
|
作者
Xing-Guo Tan and Zhu-Lin Yang Research Laboratory of Hepatobiliary Diseases
机构
关键词
pancreatic neoplasms; animal model; Ezrin; hepatocyte growth factor; C-met;
D O I
暂无
中图分类号
R735.9 [胰腺肿瘤];
学科分类号
摘要
BACKGROUND:Recent studies have confirmed that the expression of Ezrin,hepatocyte growth factor(HGF)and its receptor(C-met)is related to the genesis,progress,invasion and metastasis of some malignant tumors.Researches have also found that the biological function of Ezrin is closely related to HGF/C-met in malignant tumors.However,there is no report on the expression levels of Ezrin,HGF and C-met in rat pancreatic cancer induced by dimethylbenzanthracene (DMBA).This study aimed to detect the expression of Ezrin, HGF and C-met in rat pancreatic cancer and non-cancerous pancreatic tissues,and assess its effect in cancer induction by DMBA. METHODS:Ninety Sprague-Dawley rats were divided into 3 groups randomly:40 in a pancreatic cancer model group (group A),40 in a trichostatin A(TSA)intervention group (group B),and 10 in a control group(group C).DMBA was directly implanted into the parenchyma of rat pancreas in group A+group B.The rats of group B were treated with 1 ml of TSA saline solution(1μg/ml)via intraperitoneal injection weekly.The carcinogenesis of rats executed within 3-5 months in groups A and B was observed by macrograph and microscopy. Meanwhile,the rats in group C were executed within 5 months. The EnVision TM immunohistochemistry for detecting the expression levels of Ezrin,HGF and C-met was used in paraffinembedded sections of the pancreatic specimens. RESULTS:The incidence of pancreatic cancer in group A was 48.6%and in group B 33.3%.The maximal diameter of tumor mass was significantly larger in group A than that in group B(P<0.05).No pathological changes were observed , in the pancreas of group C and other main organs of groups A and B.The positive rates of Ezrin,HGF and C-met were significantly higher in ductal adenocarcinoma than in non- cancerous pancreatic tissues of groups A and B(P<0.01).The positive rates of Ezrin,HGF and C-met were significantly higher in ductal adenocarcinoma of group A than those in non- cancerous pancreatic tissues of group A(P<0.05),but there was no significant difference in group B(P>0.05).The positive rates of Ezrin,HGF and C-met in non-cancerous pancreatic tissues proved mild to severe atypical hyperplasia of the ductal epithelia.The pancreas of group C and 2 cases of fibrosarcoma showed the negative expression of Ezrin,HGF and C-met.There was a trend of consistency in the expression of Ezrin,HGF and C-met in ductal adenocarcinoma(P<0.05 or P<0.01). CONCLUSIONS:DMBA directly implanted into the parenchyma of the pancreas can produce a model of pancreatic cancer with a high incidence in a short time.TSA might inhibit the carcinogenesis and growth of pancreatic cancer,and its effects may be related to the inhibition of the expression of Ezrin,HGF and C-met during the process.Ezrin,HGF and C-met may have positive effects on the carcinogenesis of rat pancreas.
引用
收藏
页码:639 / 644
页数:6
相关论文
共 50 条
  • [21] Glyoxalase I (GLO1) is Up-regulated in Pancreatic Cancerous Tissues Compared with Related Non-cancerous Tissues
    Wang, Yufeng
    Kuramitsu, Yasuhiro
    Ueno, Tomio
    Suzuki, Nobuaki
    Yoshino, Shigefumi
    Iizuka, Norio
    Akada, Junko
    Kitagawa, Takao
    Oka, Masaaki
    Nakamura, Kazuyuki
    ANTICANCER RESEARCH, 2012, 32 (08) : 3219 - 3222
  • [22] Stromal reprogramming offers a novel therapeutic approach in pancreatic cancer: Implications of targeting HGF/c-MET pathway
    Pothula, S.
    Xu, Z.
    Goldstein, D.
    Pirola, R.
    Wilson, J.
    Apte, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 62 - 62
  • [23] Use of co-expression of HGF and c-Met to predict peritoneal dissemination established by autocrine HGF/c-Met signaling in gastric cancer
    Toiyama, Y.
    Tanaka, K.
    Yasuda, H.
    Saigusa, S.
    Fujikawa, H.
    Mohri, Y.
    Inoue, Y.
    Miki, C.
    Tabata, T.
    Kusunoki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [24] A Novel Adjuvant Treatment Approach in Pancreatic Cancer Via Hepatocyte Growth Factor (HGF)/c-MET Inhibition
    Pang, T. C.
    Xu, Z.
    Mekapogu, A. R.
    Pothula, S.
    Goldstein, D.
    Pirola, R.
    Wilson, J.
    Apte, M.
    PANCREAS, 2019, 48 (10) : 1504 - 1504
  • [25] c-Met in pancreatic cancer stem cells: Therapeutic implications
    Herreros-Villanueva, Marta
    Zubia-Olascoaga, Aizpea
    Bujanda, Luis
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (38) : 5321 - 5323
  • [26] c-Met in pancreatic cancer stem cells: Therapeutic implications
    Marta Herreros-Villanueva
    Aizpea Zubia-Olascoaga
    Luis Bujanda
    World Journal of Gastroenterology, 2012, (38) : 5321 - 5323
  • [27] Effects of disrupting c-Met activity with in pancreatic cancer.
    Patel, BK
    Warner, S
    Haiyong, H
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (01) : S153 - S153
  • [28] Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues
    Tsuka, H
    Mori, H
    Li, BY
    Kanamaru, H
    Matsukawa, S
    Okada, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 13 (05) : 927 - 934
  • [29] Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction
    Youngjoo Kwon
    Andrew K. Godwin
    Reproductive Sciences, 2017, 24 : 494 - 501
  • [30] Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction
    Kwon, Youngjoo
    Godwin, Andrew K.
    REPRODUCTIVE SCIENCES, 2017, 24 (04) : 494 - 501